HIGH
Semaglutide-Glycine-Cyanocobalamin Injectable, 2.5 mg, 5 mg, 1 MG/ML, 0.5 mL vials, Rx only, Northwest Compounders, Beaverton, OR
Lack of Assurance of Sterility
Quick Facts at a Glance
- Recall Date
- March 6, 2026
- Hazard Level
- HIGH
- Brand
- PAYLESS COMPOUNDERS
Hazard Information
Lack of Assurance of Sterility
What You Should Do
Consumers and healthcare providers should stop using this product immediately. Contact PAYLESS COMPOUNDERS, LLC or your healthcare provider for guidance. Notification method: Letter
Get instant alerts for PAYLESS COMPOUNDERS recalls
Be the first to know. Free instant alerts to your inbox.
No spamUnsubscribe anytime
Full Description
Semaglutide-Glycine-Cyanocobalamin Injectable, 2.5 mg, 5 mg, 1 MG/ML, 0.5 mL vials, Rx only, Northwest Compounders, Beaverton, OR. Reason: Lack of Assurance of Sterility. Classification: Class II. Quantity: 91 vials. Distribution: OR
Browse More Recalls
Safety Guide
Not sure what to do next? Our guide walks you through the process step by step.
Read: How to Get Refunds and ReplacementsWant to Know First?
Get instant alerts for recalls that affect you. Free forever.
Product Classification
Product Details
Brand
Model Numbers
Lot Number 01-27-2026@14S.5
Report Date
April 22, 2026
Source Agency
FDA - Drug SafetyRecall Status
ACTIVE